Last week’s hot topic on Scleroderma was about the Research of Lung Fibrosis in Scleroderma Reveals High Levels of Antibodies that Correlate with Disease Progression written by Margarida Azevedo.
The article talks about the study that was presented at the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, Feb. 18-20, and was titled “Antibodies Against Chemokine Receptors CXCR3 and CXCR4 as Marker for Lung Fibrosis in Patients with Systemic Sclerosis.”
Researchers at Germany’s University of Luebeck and Charité University recently presented a study where they reported that circulating antibodies against specific chemokine (small proteins with an important role in the immune system) receptors exist in higher levels in patients with systemic sclerosis, and these antibodies correlate with disease progression and clinical manifestations of the disease, such as lung fibrosis.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?